AbbVie (ABBV)

Despite its high price relative to earnings, AbbVie remains an attractive stock.

Lincoln National, AbbVie and Phillips 66 offer dividends that pay investors through midterm volatility, backed by rising rates, steady drug demand and oil risk.

They definitely matter... up to a point.

The company is gearing up for future major patent cliffs.

AbbVie's revenue lead has widened to $4 billion per quarter, but Bristol Myers shows surprising resilience despite slower growth.

AbbVie generates $17.8 billion in annual free cash flow but faces patent cliffs, while Vertex boasts a 33% net margin with concentrated cystic fibrosis exposure.

This pharma leader has a history of outperforming during rising interest rates.

They may just be getting started.

Buffett has warned about "gambling" in the market.

It was Griffin's biggest add for Citadel last quarter.

Rising rates can expose dividend traps, but this Dividend King is built to keep paying.

These funds can help you weather any storm that might be on the way.

You'd need to invest over $200,000 in the pharma leader at its current price.

AbbVie is raising its outlook with Skyrizi and Rinvoq offsetting Humira losses. Pfizer is rebuilding its pipeline around obesity drugs and key readouts expected over the next year.

The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch...

One faces patent cliffs and revenue concentration; the other dominates a booming market but trades at a premium valuation.

AbbVie trades at a 40% valuation discount but faces revenue concentration risk, while Eli Lilly's cardiometabolic dominance commands a premium.

A super-high yield isn't everything.

You'll need to generate $12,000 a year in dividends to average $1k per month from Amgen, Pfizer, J&J, AbbVie, and Bristol Myers Squibb.

These companies might bend during a downturn, but they won’t break.

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient...